Prot #C-500-01: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti–CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects with Advanced or Refractory Cancer and in Subjects who have Progre

Project: Research project

Project Details

StatusActive
Effective start/end date4/7/164/7/22

Funding

  • Agenus Inc. (Prot #C-500-01)